[Federal Register: December 6, 2007 (Volume 72, Number 234)]
[Notices]
[Page 68887]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr06de07-64]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-08-0307]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-5960 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-6974.
Written comments should be received within 30 days of this notice.
Proposed Project
Gonococcal Isolate Surveillance Project (GISP)--Revision--National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
CDC is requesting a 3-year revision with change for this project.
The objectives of GISP are to monitor trends in antimicrobial
susceptibility of strains of Neisseria gonorrhoeae in the U.S. and
characterize resistant isolates. GISP provides critical surveillance
for antimicrobial resistance, allowing for informed treatment
recommendations.
This project began in 1986 as a voluntary surveillance project and
has involved 5 regional laboratories and 30 publicly-funded, sexually
transmitted disease (STD) clinics around the country. The STD clinics
submit up to 25 gonococcal isolates per month to the regional
laboratories, which measure susceptibility to a panel of antibiotics.
Limited demographic and clinical information corresponding to the
isolates are submitted directly by the STD clinics to CDC.
During 1986-2006, GISP has demonstrated the ability to effectively
achieve its objectives. The emergence of resistance in the United
States to penicillin, tetracyclines, and now fluoroquinolones was
identified through GISP and makes ongoing surveillance critical.
Increased prevalence of fluoroquinolone-resistant N. gonorrhoeae (QRNG)
as seen in GISP data has prompted the CDC to update the treatment
recommendations for gonorrhea in the CDC's Sexually Transmitted
Diseases Treatment Guidelines, 2006 and to release an MMWR article
stating the CDC no longer recommends fluoroquinolones for treatment of
gonococcal infections (CDC, MMWR, Vol.56, No.14, 332-336). Respondents
are paid by Federal funds through the CDC Comprehensive STD Prevention
Systems, Prevention of STD-Related Infertility, and Syphilis
Elimination Grant (CSPS), for their participation in GISP network. The
estimated annualized burden for this data collection is 8,628 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
No. of Avg. burden
Type of respondent Form name No. of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Clinic.............................. Form 1................. 30 240 11/60
Laboratory.......................... Form 2................. 5 1,452 1
Form 3................. 5 48 12/60
---------------------------------------------------------------------------
Total........................... ....................... 40 ............... ...............
----------------------------------------------------------------------------------------------------------------
Dated: November 28, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer.
[FR Doc. E7-23633 Filed 12-5-07; 8:45 am]
BILLING CODE 4163-18-P